Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA, and is listed on Euronext Brussels under the symbol OXUR.
Oxurion is on a mission to transform the treatment of retinal disorders, including the development of THR-149, its novel therapeutic for the treatment of DME.
Oxurion is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people worldwide.
Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA, and is listed on Euronext Brussels under the symbol OXUR.
To prevent blindness by pioneering life changing treatments that address unmet medical needs in ophthalmology, with a focus on retinal diseases including diabetic macular edema (DME).
We are united by the shared goal of helping people to see better.
We are collaborative, resilient, and turn challenges into opportunities.
Most members of the Oxurion team hold a master’s or PhD degree. The team works at the Oxurion headquarters in Leuven (Belgium) and from remote offices across Europe and the U.S.
Each member of the Oxurion team provides a distinct viewpoint and set of experiences in the biopharmaceutical industry. The diversity and experience of the team stimulates creativity and problem-solving.
Chief Executive Officer
Chief Development Officer
Chief Legal Officer and
General Counsel
Non-Executive Director, Chairman
Chief Executive Officer
Non-Executive, Independent Director
Non-Executive, Independent Director
Non-Executive, Independent Director
To inquire regarding partnership opportunities with Oxurion, please contact:
Chief Business Officer
Chief Executive Officer
Tom Graney, has extensive global finance experience that spans corporate development, commercial strategy, portfolio management and supply chain management, communication and investor relations. He is the former Chief Financial Officer of Generation Bio, was Senior Vice President and Chief Financial Officer at Vertex Pharmaceuticals Inc. and Chief Financial Officer and Senior Vice President of Finance & Corporate Strategy at Ironwood Pharmaceuticals. Prior to Ironwood Pharmaceuticals, Mr. Graney spent 20 years working with J&J and its affiliates, serving for four years as worldwide vice president of finance and Chief Financial Officer of Ethicon. A Chartered Financial Analyst charterholder, Mr. Graney holds a B.S. in accounting from the University of Delaware and an M.B.A. in Marketing, Finance and International Business from the Leonard N. Stern School of Business at New York University.
Andy De Deene has extensive experience in drug development, including clinical development, pharmacovigilance and medical affairs. He previously worked as both Manager and Director for the Janssen Research Foundation and XCellentis in Belgium. Andy holds an MD from the University of Ghent, trained as a dermatologist at the University of Cologne, and obtained an executive MBA from Vlerick Management School.
Kathleen Paisley is Chief Legal Officer and General Counsel at Oxurion. She has acted as outside counsel to Oxurion since 2011 and has extensive experience in biotechnology and pharmaceuticals in Europe and the United States. She is a US national who has been based in Brussels, London and the Hague for most of her career. Prior to joining Oxurion, she served as a partner of Morrison & Foerster, White & Case and Ambos Lawyers, and has held previous in-house positions in London and Belgium. She is a member of the New York and D.C. bars and is triple qualified with degrees from Yale Law School, an MBA in finance and has passed the Certified Public Accountancy exam, all of which expertise she brings to bear in running the legal function at Oxurion.
Chief Business Officer
Michaël heads Corporate Development and is Secretary to the Board of Directors at Oxurion. He has gained vast experience in strategic partnering, corporate finance, and M&A. Prior to joining Oxurion, Michaël was a senior corporate development executive at Mithra Pharmaceuticals, a biotech company listed on Euronext. Before, he worked for Terumo, a Japanese stock listed medtech and pharma company. He initiated his career as a lawyer, where he developed a legal practice focusing on corporate and commercial advisory towards both private and institutional clients in the life sciences industry.
Michaël holds a master’s degree in business (Solvay Business School) and a degree corporate finance (Saïd Business School, University of Oxford), as well as a law degree (LL.M.) in both business and in health regulations (University of Antwerp and Queen Mary and Westfield College, University of London).
Non-Executive Director, Chairman
Dr. Patrik De Haes has over 25 years of experience in the global healthcare industry, covering product development, marketing and general management. Before joining Oxurion as CEO in 2008, Patrik was Head of Roche’s Global Insulin Infusion business. Prior to this, he was President and CEO of Disetronic Medical Systems Inc, a medical device company based in Minneapolis, USA. He also led the global development and commercialization of the first biotech product at Sandoz Pharma (now Novartis) in Switzerland. As past Chairman of FlandersBio, Patrik is an active member of the local and regional biotech and life sciences community in Belgium. Patrik holds a degree in Medicine from the University of Leuven.
Non-Executive, Independent Director
Thomas Clay is the Managing Member of Epacria Capital Partners, LLC, a single-family office managing public and private investments for members of the Clay family. He also serves as a Director of several private companies and of the Clay Mathematics Institute, Inc. Thomas is a graduate of Harvard College, Oxford University, and Harvard Business School. Thomas replaced his father, Landon Clay, who led the first external investment into Oxurion and resigned from the Board of Directors in 2011.